ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

darolutamide

Also written as “Darolutamide”, “Darolutamide (Nubeqa, BAY1841788)” and “Darolutamide (BAY1841788, Nubeqa)”.

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Bulbo-Spinal Atrophy, X-Linked · Neoplasms · Neoplasm Metastasis, led by 2 companies.

Drug pageDarolutamide: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 21, 202220 company-led studies, 4 open or runningNext primary completion: Jul 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer164 open or runningphase 4since Apr 21, 2022Jul 22, 2014Jul 30, 2027phase 3 · NCT05794906
Orion Corporation, Orion Pharmaits history only40 open or runningphase 2since Mar 7, 2011Mar 7, 2011none ahead

Also a collaborator on its studies: Keenova Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bayer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jul 22, 2014.

  1. Jun 6, 2016Phase 3 study in Metastatic Hormone-sensitive Prostate CancerNCT02799602 · 1,306 enrolled · United States, Australia, Belgium and more
  2. Jun 9, 2016Named darolutamideINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ODM-201
  3. Aug 29, 2016Phase 1 study in Hepatic InsufficiencyNCT02894385 · 29 enrolled · Germany
  4. Feb 8, 2017Phase 1 study in Biological AvailabilityNCT03048110 · 15 enrolled · Germany
  5. Jul 26, 2017Phase 1 study in Prostatic NeoplasmsNCT03237416 · 15 enrolled · Germany
  6. Oct 10, 2018Phase 1 study in Cerebrovascular CirculationNCT03704519 · 26 enrolled · United Kingdom
  7. Oct 21, 2019Phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT04157088 · 30 enrolled · United States
  8. Jul 7, 2020Phase 3 study in NeoplasmsNCT04464226 · 774 enrolled · United States, Argentina, Australia and more
  9. Jan 29, 2021Phase 3 study in Prostatic NeoplasmsNCT04736199 · 669 enrolled · Australia, Brazil, Canada and more
  10. Sep 17, 2021Phase 2 study in Prostatic NeoplasmsNCT05059236 · 223 enrolled · United States
  11. Apr 21, 2022Phase 4 study in Prostatic NeoplasmsNCT05348876 · 50 planned · India
  12. Aug 31, 2022Phase 2 study in Biochemically Recurrent Prostate CancerNCT05526248 · 28 enrolled · United States
  13. Mar 21, 2023Phase 3 study in Biochemically Recurrent Prostate CancerNCT05794906 · 985 enrolled · United States, Australia, Austria and more
  14. Feb 12, 2026Phase 2 study in High-risk Localized Prostate CancerNCT07450599 · 250 planned · China
  15. Nov 5, 2026Primary completion moved from 2027-04-29 to 2027-12-30Date moved laterphase 4 · +8 months · NCT05348876

Ahead

  1. Jul 30, 2027Primary completion: phase 3 study in Biochemically Recurrent Prostate CancerNCT05794906
  2. Dec 30, 2027Primary completion: phase 4 study in Prostatic NeoplasmsNCT05348876
  3. Jun 26, 2028Primary completion: phase 3 study in NeoplasmsNCT04464226
  4. Oct 15, 2028Primary completion: phase 2 study in High-risk Localized Prostate CancerNCT07450599

TargetBeta

AR →read by rule
“A formulation containing an androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 16 Bayer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07450599High-risk Localized Prostate Cancer · China2RecruitingOct 15, 2028250
NCT05794906Biochemically Recurrent Prostate Cancer · United States, Australia, Austria and more3Active, not recruitingJul 30, 2027985
NCT05526248Biochemically Recurrent Prostate Cancer · United States2CompletedAug 20, 202428
NCT05348876Prostatic Neoplasms · India4RecruitingDec 30, 202750
NCT05059236Prostatic Neoplasms · United States2CompletedMay 30, 2025223
NCT04736199Prostatic Neoplasms · Australia, Brazil, Canada and more3CompletedJun 7, 2024669
NCT04464226Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJun 26, 2028774
NCT04157088Prostatic Neoplasms, Castration-Resistant · United States2TerminatedJul 8, 202230
NCT03704519Cerebrovascular Circulation · United Kingdom1CompletedOct 1, 201926
NCT03237416Prostatic Neoplasms · Germany1CompletedOct 5, 201715
NCT03048110Biological Availability · Germany1CompletedMay 4, 201715
NCT02894385Hepatic Insufficiency · Germany1CompletedApr 10, 201729
NCT02799602Metastatic Hormone-sensitive Prostate Cancer · United States, Australia, Belgium and more3CompletedOct 25, 20211,306
NCT02671097Healthy Volunteers · Germany1CompletedMay 201630
NCT02363855Prostatic Neoplasms · Japan1CompletedNov 19, 20159
NCT02200614Prostate Cancer Non-Metastatic · United States, Argentina, Australia and more3CompletedSep 3, 20181,509

How it is read

Names in the registry

  • “Darolutamide”, 6 entries
  • “Darolutamide (Nubeqa, BAY1841788)”, 5 entries
  • “Darolutamide (BAY1841788, Nubeqa)”, 2 entries
  • “BAY1841788 (ODM-201)”, 2 entries
  • “ODM-201”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.